StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.

Several other equities analysts have also recently issued reports on the company. Northland Capmk cut Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Brookline Capital Management reaffirmed a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Finally, Northland Securities reiterated a “market perform” rating and issued a $2.00 price objective on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

Oncternal Therapeutics Stock Performance

ONCT stock opened at $0.53 on Friday. The firm has a 50 day moving average of $1.06 and a 200-day moving average of $3.75. The company has a market cap of $1.56 million, a price-to-earnings ratio of -0.05 and a beta of 1.18. Oncternal Therapeutics has a 12-month low of $0.53 and a 12-month high of $13.14.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.